[Psychopharmacotherapy of anxiety disorders in patients with cardio-vascular diseases: the use of aphobazole].

Abstract

Afobazole was administered to 32 patients, aged 18-60 years, with cardio-vascular diseases and neurotic stress-related psychopathologies and somatoform disorders (ICD-10 F40-F45). The drug was assigned in dosages from 30 to 60 mg daily (mean 50 mg) during 6 weeks, along with basic somatotropic therapy. Twenty-nine patients completed the course. Therapeutic efficacy was assessed by the Hamilton anxiety scale (HAM-A) and a subscale of the Global Clinical Impression scale (CGI). The total number of responders was 21 (70%). The improvement began from the 1st week of the treatment and increased to the 42nd day. At the same time, intensity of mental disorders (phobic, somatisized, anxiety-depressive) gradually decreased up to complete reduction. Afobazole was well-tolerated by patients.

• Authors: V E Medvedev, A P Trosnova, A V Dobrovol'skiĭ
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 107 Issue 7 Pg. 25-9 ( 2007) ISSN: 1997-7298 [Print] Russia (Federation)
• PMID: 18379478 (Publication Type: Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• 2-((2-morpholino)ethylthio)-5-ethoxybenzimidazole
• Benzimidazoles
• Morpholines

Topics

• Adolescent
• Adult
• Anxiety Disorders (complications, drug therapy)
• Benzimidazoles (therapeutic use)
• Cardiovascular Diseases (complications)
• Dose-Response Relationship, Drug
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Morpholines (therapeutic use)
• Treatment Outcome